MISSISSAUGA, ON, June 21,
2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH)
("Cipher" or the "Company") today announced that it
held its annual and special meeting of shareholders earlier today
and that all matters put forward before shareholders for
consideration and approval as set out in the Company's management
information circular dated May 10,
2023 were approved by the requisite majority of votes cast
at the meeting. In particular, shareholders approved the election
of all director nominees, the re-approval of Ernst & Young LLP
as auditor of the Company and approving the change of the location
of the Company's registered office. A total of 14,351,019 million
shares, representing 56.64% of the total shares outstanding were
represented in person or by proxy at the meeting. The detailed
results of the vote for the election of directors of Cipher is set
out below:
Nominee
|
Votes
For
|
% Votes
For
|
Votes
Withheld
|
% Votes
Withheld
|
Craig Mull
|
12,292,249
|
91.58 %
|
1,130,611
|
8.42 %
|
Harold
Wolkin
|
12,259,102
|
91.33 %
|
1,163,758
|
8.67 %
|
Douglas
Deeth
|
13,356,652
|
99.51 %
|
66,208
|
0.49 %
|
Hubert
Walinski
|
13,359,652
|
99.53 %
|
63,208
|
0.47 %
|
Craig Mull, the Company's Interim
Chief Executive Officer wishes to thank Arthur M. Deboeck, Christian Godin and Cathy Steiner for their service to the Company
and welcomes new directors Douglas
Deeth and Hubert Walinski to
the board.
Mr. Deeth has over 40 years of experience in the pharmaceutical
industry, including contract negotiations and complex transactions,
and is a founding partner and current managing partner with the law
firm of Deeth Williams Wall LLP.
Dr. Walinski is currently the Chief Scientific Officer of AIC
Global Holdings since August 2021 and
brings over 13 years' experience across medical and scientific
roles in pharmaceuticals and biotech at AstraZeneca and Boehringer
Ingelheim, both in Canada and
globally.
Craig Mull, the Company's Interim
Chief Executive Officer stated, "I am proud to announce the
appointments of Mr. Deeth and Dr. Walinski who will be able to
bring tremendous experience and insight to Cipher's future growth
opportunities."
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical
company with a robust and diversified portfolio of commercial and
early to late-stage products. Cipher acquires products that fulfill
unmet medical needs, manages the required clinical development and
regulatory approval process, and currently markets those products
either directly in Canada or indirectly through partners
in Canada, the U.S., and South America. For more
information, visit www.cipherpharma.com.
SOURCE Cipher Pharmaceuticals Inc.